Corporate information

Since its inception in 2015, Ksilink has invested approximately €40 million, funded through in-kind contributions from its members and support from high level French, European, and international consortia. ​​

The Ksiink Association has been created and raised funding to foster patient-based drug discovery in the heart of Europe through collaborations with academia and biotechs. Ksilink Services SAS has emerged from this ecosystem with a dedicated team that has acquired all technical skills to run our unique Techbio platform that now makes available its skills for customers and injects own funds in a small CNS pipeline for high revenue generation. We are open to engage into discussion for partnerships with potential investors interested in the indication fields we are working in, interested in our unique technology platform or are interested in the service business that we continue to grow.

Name: Ksilink ​

Legal name: Ksilink Services SAS​

Form: Limited company (“SAS” stands for “Société par actions simplifiée”)​

Creation: December 7, 2021​

Share capital: 900,000€ ​

Registered: in France under SIREN number 908 717 796​

VAT number: FR22908717796​

Headquarters: 16 rue Ankara 67000 Strasbourg, France​

President: Ksilink Association, represented by Alain Beretz​

CEO: Antoine de Lacombe​

Information available as of 31.12.2023​